Corcept, National Organization for Rare Disorders (NORD) sales and marketing update

Corcept launched 300 mg oral Korlym mifepristone (formerly Corlux) in the U.S. to treat Cushing's syndrome. The wholesale acquisition price for the once-daily tablet is $186. The progesterone and cortisol receptor antagonist is indicated to control hyperglycemia in adults with endogenous Cushing's syndrome who have Type II diabetes or glucose intolerance. Cushing's syndrome is a hormonal disorder caused by prolonged exposure to high levels of cortisol. Korlym has Orphan Drug designation in the U.S. and EU for the indication. ...